Abstract 4822
Background
Adenosine suppresses anti-tumor immune responses via A2aR and A2bR receptors on intra-tumoral immune cells. This effect is mediated by increased cAMP levels and phosphorylation of the transcription factor CREB. A placebo-controlled study in healthy volunteers was conducted to assess the safety, tolerability and PK/PD (pCREB levels in blood T cells) profile of AB928, in order to select AB928 doses for the ongoing studies in cancer patients.
Methods
This placebo-controlled double-blind study had single ascending dose (SAD) and multiple ascending dose (MAD) arms. AB928 doses between 10 and 200 mg qd and 100 mg bid were evaluated. Whole blood from AB928 and placebo-treated subjects was stimulated ex vivo with the adenosine agonist NECA. Flow cytometry was used to assess levels of pCREB. AB928 plasma concentrations were determined using LC-MS-MS.
Results
The study enrolled 85 participants (randomized 3:1, active:placebo), 40 each in the SAD and MAD arms, plus 5 in a food-effect assessment cohort. The effects of 1, 5 and 10 mM NECA were assessed in whole-blood samples obtained at various time points post-dose. The PD response at each timepoint was correlated with the associated AB928 plasma levels. In all dose groups, significant inhibition at peak plasma concentrations was observed. Significant inhibition was also observed 24 hours post-dose in the higher dose groups. Final unblinded safety and PK/PD results from this study will be presented.
Conclusions
AB928 was well tolerated in this study. No stopping rules were met and dose escalation continued until maximal PD effects were observed. There was no evidence of the physiological effects associated with other adenosine receptor antagonists tested in humans. The MTD was not reached in this study. Significant inhibition of A2aR-mediated CREB phosphorylation in blood T cells was observed in all dose groups at peak plasma concentrations, as well as at trough in the higher dose groups. The resulting PK/PD correlations were used to guide dose selection in several ongoing oncology studies, the outlines of which will be described in this presentation.
Clinical trial identification
EudraCT: 2017-002943-14.
Legal entity responsible for the study
Arcus Biosciences, Inc.
Funding
Arcus Biosciences, Inc.
Editorial Acknowledgement
Disclosure
L.C. Seitz, D. Ashok, M. Leleti, J. Powers, B. Rosen, D. Miles, E. Sharif, L. Jin, A. Park, S. Young, A. Rieger, U. Schindler, J. Karakunnel, M. Walters: Employee and stock owner: Arcus.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract